Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human nerve growth factor
- Development stage
- Unknown
- Lead developer
- Dompé
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Recombinant human nerve growth factor (rhNGF) is a biologic neurotrophin that was investigated for the treatment of HIV-associated sensory neuropathy. It acts as an agonist for the High affinity nerve growth factor receptor (TrkA) located on small-diameter sensory neurons in the peripheral nervous system. By stimulating these neurons, rhNGF aims to promote the survival and regeneration of damaged nerve fibers, addressing the underlying pathology of painful neuropathy. The National Institute of Allergy and Infectious Diseases (NIAID) sponsored a Phase II clinical trial (ACTG 291) to evaluate its safety and efficacy. Although the study showed positive trends in pain reduction and sensory improvement, the clinical development was hindered by side effects such as injection site pain.
- Other names
- Nerve Growth Factor, Recombinant HumanrhNGF
02
Targets
NGFR (p75NTR)NTRK1 (Tropomyosin-related receptor kinase A)A2M (Alpha-2-macroglobulin)
Beyond the preview
Go deeper on recombinant human nerve growth factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human nerve growth factor.